CLINICAL TRIALS PROFILE FOR PERMETHRIN

505(b)(2) Clinical Trials for permethrin

This table shows clinical trials for potential 505(b)(2) applications. See the next table for all clinical trials

Trial Type	Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
OTC	NCT00244439 ↗	Safety and Efficacy of a Novel Malathion Formulation in the Treatment of Head Lice	Completed	Taro Pharmaceuticals USA	Phase 3	2005-12-01	Current treatments for head lice include over-the-counter products such as permethrin and prescription products such as OVIDE (malathion 0.5%) lotion. In a previous phase II study, a novel, easy-to-use malathion 0.5% formulation was found to be a safe treatment for head lice. The current study will compare the efficacy and safety of this novel formulation of malathion with OVIDE and with an over-the-counter permethrin product.
New Formulation	NCT00927472 ↗	Efficacy, Safety and Tolerability of a Novel Malathion Formulation in Patients 2 Years and Older With Head Lice	Completed	Taro Pharmaceuticals USA	Phase 3	2009-08-01	In this study, Malathion Gel 0.5% will be compared to Nix (permethrin 1%) as a treatment for head lice in patients 2 years of age and older. Malathion Gel 0.5% is a new formulation of an established head lice treatment. The new formulation has been evaluated in 2 previous studies of patients 2 years of age and older.
New Formulation	NCT00963508 ↗	Efficacy, Safety and Tolerability of a Novel Malathion Formulation in Patients 2 Years and Older With Head Lice	Completed	Taro Pharmaceuticals USA	Phase 3	2009-08-01	In this study, Malathion Gel 0.5% will be compared to Nix (permethrin 1%) as a treatment for head lice in patients 2 years of age and older. Malathion Gel 0.5% is a new formulation of an established head lice treatment. The new formulation has been evaluated in 2 previous studies of patients 2 years of age and older.
OTC	NCT01514513 ↗	Efficacy and Safety of Licefreee Spray Against Nix 1% Permethrin	Completed	South Florida Family Health and Research Centers	N/A	2011-08-01	The purpose of this study is to evaluate the safety and efficacy of Licefreee Spray in eradicating head lice as compared to Nix, both are available over-the-counter lice treatments.
OTC	NCT05643820 ↗	Comparison of Oral Ivermectin and Permethrin 5% Lotion in Treatment of Pediculosis Capitis	Completed	Combined Military Hospital Abbottabad	Phase 1	2022-03-01	In children, pediculosis is a common ectoparasitic infestation. Infestation of head lice (Pediculus humanus capitis) causes a variety of physical symptoms, including pruritus, excoriation, cervical lymphadenopathy, and conjunctivitis1. It also has a number of negative social consequences, including parental anxiety and stigmatization of infested children2. It is a significant public health issue that primarily affects school-aged children aged 8 to 113. In developing nations, prevalence rates of up to 40% have been reported4. The four urban areas of KPK (NWFP) reported prevalence of 36.7%5. People with a low socioeconomic background and poor hygiene are more likely to be affected6. Pediculosis capitis has been treated using a variety of treatment modalities. They include both physician prescription and over-the-counter medications. Permethrin or ivermectin had been used topically or orally. Permethrin is a neurotoxin that is synthesized. It is a pyrethroid neurotoxic that targets voltage-sensitive Sodium ion receptors in the neurological system of the insect, triggering nerve depolarization, hyperexcitation, muscular paralysis, and, eventually, parasite death7. Ivermectin is antiparasitic medication, it is possible to treat diseases like lymphatic filariasis, and ectoparasite infestations, primarily scabies, with ivermectin because it binds to glutamate gated chloride ion receptors of invertebrates and disrupts neurotransmission8. The rationale of this study is to study while comparing effectiveness of oral ivermectin and topical permethrin in management of pediculosis. The topical medication usage is problematic and had reported drug resistance9. There has been less regional or national research on the effectiveness of oral Ivermectin, so doctors less frequently use it in our department. Instead, the patients are treated for pediculosis capitis with topical Permethrin.

All Clinical Trials for permethrin

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00244439 ↗	Safety and Efficacy of a Novel Malathion Formulation in the Treatment of Head Lice	Completed	Taro Pharmaceuticals USA	Phase 3	2005-12-01	Current treatments for head lice include over-the-counter products such as permethrin and prescription products such as OVIDE (malathion 0.5%) lotion. In a previous phase II study, a novel, easy-to-use malathion 0.5% formulation was found to be a safe treatment for head lice. The current study will compare the efficacy and safety of this novel formulation of malathion with OVIDE and with an over-the-counter permethrin product.
NCT00262418 ↗	Comparison of the Efficacy and Safety of Ivermectin to Permethrin	Completed	University Ghent	Phase 2	2004-07-01	Comparison of the efficacy and safety of a single administration of ivermectin to a single administration of permethrin for the treatment of scabies
NCT00376155 ↗	Comparison of Two Strategies for the Delivery of IPTc	Completed	Medical Research Council	Phase 4	2006-05-01	Antimalarial chemoprophylaxis can reduce morbidity and mortality from malaria in children. However, this approach to malaria control has not been implemented widely because of concerns over its possible effect on the development of resistance and natural immunity. Intermittent preventive treatment (IPT) may be able to achieve some of the beneficial effects of chemoprophylaxis without its drawbacks. Recently, it has been shown that IPT given to Senegalese children under the age of five years on three occasions during the malaria transmission season reduced the incidence of clinical malaria by approximately 90%. However, it is uncertain how this intervention can be most effectively delivered. Therefore, 26 Maternal and Child Health (MCH) trekking clinics in Upper River Division, south of the River Gambia, each with an average catchment population of 400-500 children under 5 years of age, will be randomly allocated to receive IPT from the MCH trekking team or from a IPT dispenser (village health worker, traditional birth attendant or a community mother based in a primary health care village). Treatment with a single dose of sulfadoxine /pyrimethamine (SP) plus three doses of amodiaquine will be given to all study subjects at monthly intervals on three occasions during the months of September, October and November. The primary end points will be the incidence of clinical attacks of malaria detected by passive case detection, and cost-effectiveness of the delivery methods. Important secondary endpoints will be the coverage and the equity of coverage of IPT in preventing malaria morbidity.
NCT00376155 ↗	Comparison of Two Strategies for the Delivery of IPTc	Completed	Gates Malaria Partnership	Phase 4	2006-05-01	Antimalarial chemoprophylaxis can reduce morbidity and mortality from malaria in children. However, this approach to malaria control has not been implemented widely because of concerns over its possible effect on the development of resistance and natural immunity. Intermittent preventive treatment (IPT) may be able to achieve some of the beneficial effects of chemoprophylaxis without its drawbacks. Recently, it has been shown that IPT given to Senegalese children under the age of five years on three occasions during the malaria transmission season reduced the incidence of clinical malaria by approximately 90%. However, it is uncertain how this intervention can be most effectively delivered. Therefore, 26 Maternal and Child Health (MCH) trekking clinics in Upper River Division, south of the River Gambia, each with an average catchment population of 400-500 children under 5 years of age, will be randomly allocated to receive IPT from the MCH trekking team or from a IPT dispenser (village health worker, traditional birth attendant or a community mother based in a primary health care village). Treatment with a single dose of sulfadoxine /pyrimethamine (SP) plus three doses of amodiaquine will be given to all study subjects at monthly intervals on three occasions during the months of September, October and November. The primary end points will be the incidence of clinical attacks of malaria detected by passive case detection, and cost-effectiveness of the delivery methods. Important secondary endpoints will be the coverage and the equity of coverage of IPT in preventing malaria morbidity.
NCT00376155 ↗	Comparison of Two Strategies for the Delivery of IPTc	Completed	London School of Hygiene and Tropical Medicine	Phase 4	2006-05-01	Antimalarial chemoprophylaxis can reduce morbidity and mortality from malaria in children. However, this approach to malaria control has not been implemented widely because of concerns over its possible effect on the development of resistance and natural immunity. Intermittent preventive treatment (IPT) may be able to achieve some of the beneficial effects of chemoprophylaxis without its drawbacks. Recently, it has been shown that IPT given to Senegalese children under the age of five years on three occasions during the malaria transmission season reduced the incidence of clinical malaria by approximately 90%. However, it is uncertain how this intervention can be most effectively delivered. Therefore, 26 Maternal and Child Health (MCH) trekking clinics in Upper River Division, south of the River Gambia, each with an average catchment population of 400-500 children under 5 years of age, will be randomly allocated to receive IPT from the MCH trekking team or from a IPT dispenser (village health worker, traditional birth attendant or a community mother based in a primary health care village). Treatment with a single dose of sulfadoxine /pyrimethamine (SP) plus three doses of amodiaquine will be given to all study subjects at monthly intervals on three occasions during the months of September, October and November. The primary end points will be the incidence of clinical attacks of malaria detected by passive case detection, and cost-effectiveness of the delivery methods. Important secondary endpoints will be the coverage and the equity of coverage of IPT in preventing malaria morbidity.
NCT00604084 ↗	Veron Scabies Education and Eradication Program	Completed	Edward Via Virginia College of Osteopathic Medicine	N/A	2007-05-01	The purpose of this project is to develop a community scabies eradication and education program for the highly endemic areas surrounding the Veron community on the eastern tip of the Dominican Republic. It proposes the use of oral Ivermectin as a replacement for topical Lindane--a readily available medical formulation, pesticide, and environmental toxin that is reported to be banned in the Dominican Republic as well as over 80 other countries throughout the world.

Clinical Trial Conditions for permethrin

Condition Name

Condition Name for permethrin
Intervention	Trials
Scabies	22
Pediculosis Capitis	4
Head Lice	3
Pediculosis	3

Condition MeSH

Condition MeSH for permethrin
Intervention	Trials
Scabies	23
Lice Infestations	10
Parasitic Diseases	5
Malaria	2

Clinical Trial Locations for permethrin

Trials by Country

Trials by Country for permethrin
Location	Trials
United States	45
France	13
Pakistan	5
El Salvador	2
Solomon Islands	2

Trials by US State

Trials by US State for permethrin
Location	Trials
Florida	12
California	8
Texas	6
Pennsylvania	5
Arkansas	3

Clinical Trial Progress for permethrin

Clinical Trial Phase

Clinical Trial Phase for permethrin
Clinical Trial Phase	Trials
PHASE4	1
PHASE3	2
PHASE2	1

Clinical Trial Status

Clinical Trial Status for permethrin
Clinical Trial Phase	Trials
Completed	21
Recruiting	5
NOT_YET_RECRUITING	3

Clinical Trial Sponsors for permethrin

Sponsor Name

Sponsor Name for permethrin
Sponsor	Trials
bioRASI, LLC	4
London School of Hygiene and Tropical Medicine	3
ParaPRO LLC	3

Sponsor Type

Sponsor Type for permethrin
Sponsor	Trials
Other	44
Industry	30
U.S. Fed	2

Last updated: July 28, 2026

Permethrin clinical trials update, market analysis, and projection

Permethrin’s clinical development footprint is small relative to its established use as an antiparasitic insecticide. Public trial activity is dominated by formulation, bioequivalence, and resistance/field-performance studies rather than new molecular-entity development. Market sizing and forward projections track the over-the-counter (OTC) and prescription insecticide supply chain, with demand driven by scabies, lice, and agricultural pest control cycles.

Clinical trials update snapshot (public domain focus)

Permethrin’s most visible “clinical” activity in recent years is not new mechanism-of-action innovation; it is:

• New or updated topical formulations (cream, lotion, and device-combination products).
• Comparative and efficacy studies aligned to clinical endpoints used for head lice and scabies.
• Resistance monitoring efforts and field trials to quantify response rates after prior exposure patterns.

Because permethrin is widely generic and formulary-based, trial reporting is often fragmented across regions, sponsor types (generic manufacturers, distributors, academic groups), and study designs (comparative efficacy, field effectiveness, and safety surveillance).

Market analysis snapshot

Permethrin is sold across multiple segments, with the biggest market relevance typically coming from:

1. Human dermatology: head lice and scabies OTC and prescription topical use.
2. Veterinary: ectoparasite control in animals (depends on local approvals).
3. Agriculture and public health: pest and vector control for household, crop, and mosquito-related uses in many jurisdictions.

Commercial performance is affected by:

• Product switching among topical agents (pyrethroids vs non-pyrethroid alternatives).
• Resistance pressure to pyrethroids (notably in head lice in certain geographies).
• Regulatory and labeling changes (safety updates and use restrictions).
• Supply chain and pricing for bulk insecticide intermediates and generic topical finished doses.

Market projection (directional)

Near- and mid-term growth is expected to be modest and driven by:

• Continued demand for OTC scabicide/lice products, supported by persistent prevalence cycles.
• Ongoing formulation upgrades and brand/generic mix shifts that protect margins even when unit volumes are stable.
• Substitution by alternative actives in geographies with higher resistance prevalence, limiting upside.

The most defensible projection approach for permethrin is segment-based (human topical vs veterinary vs agriculture/public health) and then mapped to local regulatory status and resistance trends. Without a single unified, permissioned dataset covering all regions, a single-point global “forecast number” is not reliable for decision-making.

---

Permethrin clinical trials update: what new studies are emerging for scabies and head lice?

Featured snippet answer: Recent permethrin trial activity is largely formulation and comparative-efficacy oriented in head lice/scabies rather than new drug-invention studies.

What types of permethrin studies are most common?

• Comparative clinical efficacy: permethrin vs other topical actives (often within the same class or in step-up regimens).
• Resistance or susceptibility monitoring: observational or laboratory-correlated studies tied to field outcomes.
• Safety and tolerability: pediatric and sensitive-population safety, skin irritation, and adverse-event profiling.
• Pharmacotechnical updates: stability, vehicle optimization, and delivery system performance studies.

What endpoints dominate permethrin efficacy trials?

• Head lice: reduction in live lice counts at defined timepoints, with criteria aligned to regulatory expectations.
• Scabies: lesion improvement and symptom resolution timepoints, plus parasitological confirmation in controlled assessments.

How to interpret “trial updates” for permethrin

For established actives, “updates” generally do not change clinical positioning; they change:

• which formulation is marketed,
• which generic is substitutable,
• and whether the product is expected to meet labeling efficacy claims in the target population.

---

What is permethrin’s current regulatory status in major markets (FDA, EMA, and key geographies)?

Featured snippet answer: Permethrin is an approved insecticidal active used in topical human antiparasitic products and multiple non-human categories depending on jurisdiction; approvals are product- and formulation-specific.

United States (FDA)

Permethrin topical products are generally marketed under established drug or OTC frameworks depending on the specific product and labeling category. For US competitive landscape and exclusivity, the Orange Book is relevant for NDA/BLA/ANDA listings tied to specific permethrin formulations.

Europe (EMA / national authorities)

Permethrin use in the EU is split across:

• medicinal products for scabies/lice under national licensing,
• and biocidal/plant protection authorization regimes depending on use context.

Key compliance driver: product labeling

Permethrin’s practical regulatory “value” is frequently driven by:

• label indications,
• pediatric age restrictions,
• application regimen details,
• and safety language updates.

---

What patents protect permethrin topical products (cream and lotion) and how many patents cover the life cycle?

Featured snippet answer: Permethrin itself is a long-established active, so patent estates typically cluster around specific formulations, process improvements, and packaging rather than the underlying molecule.

How permethrin patent landscapes usually break down

• Composition/formulation patents: vehicle systems, stabilizers, or delivery improvements that support a specific commercial product.
• Method-of-use patents: dosing regimens or specific patient subgroups (less common for an old active but still possible for certain formulations).
• Process and manufacturing patents: mixing, purification, crystallization, or scale-up improvements.
• Packaging and device patents: applicator and dispensing mechanisms.

Why “how many patents” is hard to answer globally

Permethrin’s global generic ubiquity means:

• multiple jurisdictions have different protection sets,
• many patents expire, lapse, or are not tracked uniformly across commercial product lines.

For market entry and enforcement, the relevant question is rarely total patent count; it is whether any active, enforceable US or EU patents still cover the marketed finished-dose form.

---

When does permethrin lose exclusivity: expiration dates for formulation and method patents?

Featured snippet answer: For most permethrin topical products, major exclusivity has already expired, leaving late-cycle protection mostly limited to specific formulation/process patents rather than active-molecule exclusivity.

Typical exclusivity outcomes for permethrin

• Newer “exclusive” periods usually come from formulation differentiation rather than molecule invention.
• Most products revert quickly to multi-source supply once any formulation patents expire.

---

Which companies are challenging permethrin products via Paragraph IV or biosimilar-style pathways?

Featured snippet answer: Paragraph IV is relevant only where a permethrin product is under patent-protected NDA/BLA with Orange Book listings; most permethrin actives and mainstream products have limited remaining patent hooks compared with modern brand drug portfolios.

How to evaluate competitive entry risk

For topical permethrin, generic entry risk is driven by:

• whether an innovator listed a patent in Orange Book for that specific strength/form,
• whether any method-of-use patent applies,
• and whether courts enjoin or settle entry.

---

What formulations are protected by permethrin patents (vehicles, strengths, and delivery systems)?

Featured snippet answer: Patent coverage, where present, tends to map to specific vehicles and application formats (cream vs lotion, concentration, and excipient sets) rather than permethrin chemistry.

Common formulation themes in antiparasitic topicals

• Vehicle viscosity and spread characteristics for application reliability.
• Skin penetration or retention properties tied to vehicle engineering.
• Stabilization and shelf-life controls.

---

What patent litigation affects permethrin topical products?

Featured snippet answer: Litigation exists mainly around specific formulation/process patents tied to particular branded products or long-tail enforcement. Broad, molecule-level litigation is uncommon given permethrin’s age.

Litigation drivers

• Orange Book patent disputes tied to generic substitution.
• Settlement terms that delay or permit entry.
• Claims around vehicle equivalence or non-infringement of formulation/process parameters.

---

What generic entry risks exist for permethrin (US ANDA scenarios)?

Featured snippet answer: Generic substitution risk is generally moderate given widespread availability, but entry timing can still be affected by product-specific active patents listed for particular strengths and dosage forms.

How to assess ANDA timing risk in practice

• Identify whether any patents listed for the specific permethrin strength are still enforceable.
• Determine if patents are formulation/process or method-of-use.
• Check whether any litigation or settlement affects entry.

---

How does permethrin compare with alternative actives for scabies and head lice (market and IP implications)?

Featured snippet answer: Permethrin’s commercial performance is constrained by resistance and therapeutic substitution by other actives, which can reduce demand in high-resistance settings.

Competitive substitutions that can pressure permethrin demand

• Non-pyrethroid topical alternatives for scabies/lice where permitted.
• Combination regimens in certain labeled protocols.
• Repeated treatment cycles that shift preference toward actives with higher practical cure rates in resistant regions.

IP implication

Competition pressures can shift R&D toward:

• improved formulations that maintain efficacy against partially resistant populations,
• or new delivery systems (devices, engineered vehicles).

---

Permethrin market analysis: where is demand concentrated and what drives volume?

Featured snippet answer: Permethrin demand is concentrated in human topical antiparasitics (head lice, scabies), with additional scale from veterinary and public health/agricultural uses depending on country.

Demand drivers

• Epidemiology: outbreaks drive temporary spikes in lice and scabies treatments.
• Household transmission dynamics: lice demand rises with school and household clustering patterns.
• Resistance trends: reduced effectiveness can shift consumer/prescriber behavior to alternatives.
• Pricing and payer/channel structure: OTC vs prescription mix affects volume and revenue.

Supply-side drivers

• availability of bulk insecticide inputs,
• manufacturing scale and stability constraints for topical products,
• regulatory compliance and label maintenance costs.

---

Permethrin revenue projection: what growth rates are plausible and what could break the trend?

Featured snippet answer: Global permethrin market growth is expected to be low to mid-single digits in value terms, with upside limited by resistance and substitution, and downside tied to regulatory restrictions or input-cost volatility.

Bull cases

• Sustained OTC penetration with stable resistance outcomes.
• Continued stable agricultural/public health spending in vector-control programs.
• Formula and packaging upgrades that improve brand/generic price resilience.

Bear cases

• Expansion of resistance leading to substitution away from pyrethroids.
• Tightening of labeling/usage restrictions in key markets.
• Commodity input cost volatility or supply disruptions.

What to model in a forecast

A defensible projection framework:

1. Segment volumes by use category (human vs veterinary vs agricultural/public health).
2. Apply price-per-unit trajectories by category (OTC pricing differs from institutional vector-control spend).
3. Overlay resistance impacts by geography.
4. Include regulatory adjustments and competitive active substitution.

---

Key Takeaways

• Permethrin clinical updates are mostly formulation/comparative efficacy and field-performance oriented, not new MOA discovery.
• Market demand persists across human antiparasitic use and additional non-human insecticide channels, with performance strongly influenced by pyrethroid resistance patterns.
• Projections should be segment- and geography-based, with resistance and substitution acting as the primary upside/downside levers.
• Patent and exclusivity leverage for permethrin is generally limited to specific formulations/processes where still in force; molecule-level exclusivity is largely exhausted.

---

FAQs

1) Does permethrin still have meaningful patent protection in the US for lice/scabies products?
Answer: Protection is typically product-specific and often limited to formulation/process patents rather than molecule-based exclusivity.

2) How does permethrin resistance in head lice affect real-world market performance?
Answer: It shifts consumer and prescriber preferences to alternatives, reducing demand in affected geographies and increasing repeat-treatment and switching behavior.

3) Are there ongoing scabies clinical studies with permethrin versus newer comparators?
Answer: Most current activity focuses on comparative efficacy, safety, and regimen performance aligned to labeled endpoints rather than new mechanism studies.

4) What regulatory framework governs permethrin topical antiparasitic products in the EU compared with the US?
Answer: The US is driven by medicinal product approval pathways for specific finished doses, while the EU splits across medicinal and biocidal/other authorization regimes depending on use.

5) What forecast assumptions matter most for permethrin revenue projections?
Answer: Segment pricing, geographic resistance prevalence, and regulatory/label stability dominate the near-to-mid term.

---

References (APA)

1. FDA Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. U.S. Food and Drug Administration.
2. EMA medicines database. European Medicines Agency.
3. U.S. National Library of Medicine. ClinicalTrials.gov.